Get the Stockscreener App
74.08
0.93%
-0.63
Edwards Lifesciences Corp stock is traded at $74.08, with a volume of 396.16K.
It is down -0.93% in the last 24 hours and up +5.78% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$74.71
Open:
$74.31
24h Volume:
396.16K
Relative Volume:
0.09
Market Cap:
$44.06B
Revenue:
$5.72B
Net Income/Loss:
$4.17B
P/E Ratio:
10.63
EPS:
6.97
Net Cash Flow:
$490.10M
1W Performance:
-2.85%
1M Performance:
+5.78%
6M Performance:
+5.60%
1Y Performance:
-14.58%
1-Day Range:
$73.50
$74.66
1-Week Range:
$73.50
$76.67
52-Week Range:
$58.93
$96.12
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
74.04 | 44.06B | 5.72B | 4.17B | 490.10M | 6.97 |
|
ABT
Abbott Laboratories
|
134.55 | 230.98B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
105.53 | 155.49B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
385.40 | 147.45B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
89.71 | 112.85B | 33.20B | 4.26B | 5.47B | 3.29 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Pittenger & Anderson Inc. Grows Stock Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
AlphaCentric Advisors LLC Makes New $691,000 Investment in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Baillie Gifford & Co. Buys 498,100 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Kentucky Retirement Systems Insurance Trust Fund Has $287,000 Stock Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Ownership Capital B.V. Sells 200,754 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Position Lessened by Chevy Chase Trust Holdings LLC - MarketBeat
CIBC Asset Management Inc Sells 31,973 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Rhumbline Advisers Sells 37,002 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
WD Rutherford LLC Cuts Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Holdings Raised by Empower Advisory Group LLC - MarketBeat
First Merchants Corp Has $773,000 Stock Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Leavell Investment Management Inc. Sells 6,450 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Peering Into Edwards Lifesciences's Recent Short Interest - Benzinga
Edwards Lifesciences Co. (NYSE:EW) Director Steven R. Loranger Sells 5,739 Shares - MarketBeat
Vontobel Holding Ltd. Cuts Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences (NYSE:EW) Stock Rating Lowered by Wolfe Research - MarketBeat
Edwards Lifesciences (NYSE:EW) Price Target Raised to $75.00 - MarketBeat
Scott B. Ullem Sells 11,250 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock - MarketBeat
Edwards Lifesciences' SWOT analysis: stock faces TAVR headwinds, TMTT potential - Investing.com
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MSN
FY2025 EPS Forecast for Edwards Lifesciences Cut by Analyst - MarketBeat
Capital Advisors Inc. OK Decreases Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences (NYSE:EW) Shares Gap Up After Strong Earnings - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Savant Capital LLC - MarketBeat
New York State Teachers Retirement System Sells 42,203 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
26,922 Shares in Edwards Lifesciences Co. (NYSE:EW) Acquired by Asset Planning Inc - MarketBeat
Edwards Lifesciences (NYSE:EW) Price Target Raised to $71.00 at Canaccord Genuity Group - MarketBeat
Edwards Lifesciences (NYSE:EW) Issues FY 2025 Earnings Guidance - MarketBeat
Edwards Lifesciences (NYSE:EW) Releases Q1 2025 Earnings Guidance - MarketBeat
Van ECK Associates Corp Has $12.67 Million Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Morgan Stanley Issues Positive Forecast for Edwards Lifesciences (NYSE:EW) Stock Price - MarketBeat
Edwards Lifesciences (NYSE:EW) Price Target Cut to $73.00 by Analysts at Evercore ISI - MarketBeat
Piper Sandler Increases Edwards Lifesciences (NYSE:EW) Price Target to $73.00 - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Q4 2024 Earnings Call Transcript - MSN
Edwards Lifesciences (NYSE:EW) Issues Earnings Results - MarketBeat
AustralianSuper Pty Ltd Has $197.57 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Bogart Wealth LLC Increases Stock Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. Sells 6,500 Shares - MarketBeat
Edwards Lifesciences Director Sells Shares - TradingView
Barclays Increases Edwards Lifesciences (NYSE:EW) Price Target to $90.00 - MarketBeat
Insider Unloading: LESLIE HEISZ STONE Sells Options, Realizes $179K - Benzinga
Ingalls & Snyder LLC Sells 3,463 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Entropy Technologies LP Sells 17,004 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Executives at Edwards Lifesciences Corp Execute Stock Transactions - TradingView
Earnings call transcript: Edwards Lifesciences Q4 2024 beats estimates, stock surges - MSN
Daiwa Adjusts Price Target on Edwards Lifesciences to $77 From $72, Maintains Neutral Rating - Marketscreener.com
Royal Bank of Canada Reaffirms Outperform Rating for Edwards Lifesciences (NYSE:EW) - MarketBeat
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.75%
0.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):